At first glance, their paths may seem parallel, unlikely to cross or interact
Importantly, the FDA labeling cautions against using semaglutide in patients with severe gastrointestinal disease, including severe gastroparesis
19,20 With respect to the latter, given that CKD patients have impaired renal excretion of iodine, they may be at even greater risk for thyroid complications ensuing from excess iodine intake from dietary and/or medication sources as compared with the general population
Route: Intramuscular (IM) or intravenous (IV) injection
The SELECT study: a warning In 2023, semaglutide was shown to reduce the rates of major adverse cardiovascular events by 20% among persons with a history of atherosclerotic cardiovascular disease and obesity or in persons with overweight and one or more weight-related complications [79]
2023 Sep 7;389(10):877-888